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a b s t r a c t
INTRODUCTION: Idiopathic granulomatous mastitis (IGM) is becoming more commonly recognized and
reported more often. Currently, many recommend corticosteroids in its management.
PRESENTATIONOF CASE:A 34-year-old G3P2Hispanic female, 28weeks pregnant, presentedwith a 19 cm
right breast mass. She had a known prolactinoma treated with bromocriptine which was discontinued
during her pregnancy. Ultrasound guided core biopsy procedure revealed granulomatous mastitis. The
patient was told that themasswould resolvewith observation. The patient seen at another institution by
an infectious disease specialist who started treatment with amphotericin for presumptive disseminated
coccidioidomycosis. Repeated titers were negative for coccidioides antibody. Repeat cultures were nega-
tive as well. Due to the persistence of the infectious disease specialist, tissue cultures were performed on
fresh tissue specimens, which did not grow bacterial, fungal, nor acid fast organisms. The amphotericin
regimen resulted in no improvement of her breastmass after 10weeks.Within twoweeks of stopping the
antifungal therapy, however, themass diminished to 6 cm. The patient delivered at 39weeks. Bromocrip-
tine was restarted, and within 4 weeks, the lesion was no longer palpable. She had not shown signs of
recurrence for 32 months.
DISCUSSION: Treatment recommendations for IGM vary widely but antibiotics and antifungal medi-
cations are not recommended. Corticosteroid treatment is most commonly recommended, however,
outcomes may not be different from management with observation. Prolactin may be involved in the
pathophysiology of the process.
CONCLUSION: IGM is becoming recognized more frequently. Observation and patience with natural his-
tory can be an effective management.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Idiopathic granulomatous mastitis (IGM) was an uncommon
disease of the breast that is now being recognized and reported
more commonly [1–3]. It occurs most often in fertile, parous
women, in the fourth decade of life, can have a prolonged natural
history, and can be recurrent [4–9]. By deﬁnition, IGM is a disease
with no known cause and can only be diagnosedwhen other etiolo-
gies have been ruled out (i.e., malignancy, infection most notably
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tuberculosis, and the systemic diseases sarcoidosis or Wegener’s
granulomatosis) [4,9].
Patients with IGM have a variety of presentations. Most com-
monly a breast mass with or without pain and sometimes with
associated skin ulcerations and sinus tract formation. Most con-
cerning is that, IGMmaypresentwith ﬁndings suspicious for breast
cancer such as a large palpable mass and associated skin changes.
As with nearly all palpable masses, because of the dangers inher-
ent in the differential diagnosis, histologic diagnosis with needle
biopsy is necessary. On biopsy, IGM shows characteristic non-
caseating granulomas, inﬂammation, and microabscess formation
conﬁned to the lobule. Following diagnosis, treatment modali-
ties vary widely. These include excision of lesion, steroid therapy,
chemotherapy such as methotrexate, and observation. None of
http://dx.doi.org/10.1016/j.ijscr.2015.02.051
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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thesemodalitieshasbeen showntobe superior to closeobservation
[1–3,9].
The case presented is the management of a pregnant woman
with a prolactinoma and a large mass determined to be idiopathic
granulomatous mastitis.
2. Presentation of case
A 34-year-old G3P2 Hispanic female born in Mexico presented
with a painful enlarging right breast mass for one month. She pre-
sented at 25 weeks intrauterine pregnancy. She previously was
given a course of cephelexin followed by dicloxacillin at an unafﬁl-
iated institution with minimal subjective improvement. Her past
medical history was signiﬁcant for a prolactinoma treated with
bromocriptine. The medication, however, had been discontinued
during her pregnancy. On review of systems she had a one week
history of erythema nodosum on bilateral lower legs; and denied
fever, chills, cough, nausea and vomiting.
Physical examination revealed a non-ill appearing, well nour-
ished, pregnant female with a 19 cm right breast mass with breast
skin edema, induration, and some nipple distortion. Ultrasound did
not identify a distinctmass andmammographywas not performed.
An ultrasound guided vacuum assisted core biopsy procedure was
performed and 12 core samples were taken from various portions
of the lesion. Breast tissue was submitted to pathology and micro-
biology for bacterial, fungal and acid fast bacilli (AFB) cultures.
Histologic diagnosis revealed granulomatous mastitis character-
ized by granulomatous inﬂammatory reaction centered on lobules
and composed of epithelioid histiocytes, multinucleated giant
cells with admixed lymphocytes, plasma cells and eosinophils
(Figs. 1 and 2). All cultures and stains were negative for organisms.
The patient was told that the mass would resolve with observation
and that no further treatmentwouldbenecessary. Shewas also told
that the course of the disease process, however, can have periods
of exacerbation and require up to 18 months to resolve.
Fifteendays later, shepresented to thebreast clinicwith a breast
ﬂuid collection in the same location as the mass. A drainage pro-
cedure was performed through an 11 blade stab incision using a
12 gage vacuum core needle biopsy device in the clinic. The vac-
uum feature was used to remove the necrotic liqueﬁed tissue. The
mass was approximately 15 cm after the drainage procedure. A
second ﬂuid collection then occurred and she sought treatment
at an emergency room of an unafﬁliated hospital. There she was
seen by an infectious disease specialist who started treatmentwith
amphotericin for presumptive disseminated coccidioidomycosis.
The patient had a second core needle vacuum drainage procedure
to remove the ﬂuid collection. Repeated titers were negative for
Fig. 1. Hematoxylin and eosin stain showing a normal breast lobule in the upper
left corner. The tissue on the right side shows ﬁndings of granulomatous masti-
tis with granuloma and multinucleated giant cell located immediately beneath the
granuloma (100× magniﬁcation).
Fig. 2. Hematoxylin and eosin stain showing necrotic granulomawithmicroabscess
formation (200× magniﬁcation).
coccidioides antibody. Repeat cultures were negative as well. The
infectious disease specialist remained concerned that titers were
unreliable due to the patient’s pregnancy. Coccidioides immitis
titers failed to convert over time. The infectious disease specialist
felt that fresh tissue was required to reliably rule out Coccidioides.
Tissue cultureswere performed on fresh tissue taken on two subse-
quent core needle biopsy specimens. These specimens did not grow
bacterial, fungal, nor acid fast organisms. In addition, unﬁxedbreast
tissue from this patient was submitted to the University of Wash-
ington for polymerase chain reaction (PCR) analysis for fungal, AFB
and bacterial organisms, and was negative as well. Additionally,
Coccidioides specieswas not detected using PCR. The amphotericin
regimenwas stoppedafter 10weeks of treatmentwithno improve-
ment of her breast mass.
Subsequently, within two weeks of stopping the antifungal
therapy, the lesion diminished in size from 15cm to 6 cm. The
patient delivered at 39 weeks. At initial postpartum visit her mass
was still 6 cm. Two weeks later bromocriptine was restarted, and
within 4 weeks, the lesion was no longer palpable. She had not
shown signs of recurrence for 32 months after resolution of the
mass.
The patient was then seen at 33 months after resolution. At
this time she complained of a new developing area of swelling
in her right breast for 1–2 weeks. On examination she did have
a 1 cm area of swelling clinically consistent with early granuloma-
tous mastitis. It turned out the patient had missed appointments
with her endocrinologist and therefore, had been off bromocriptine
for approximately 5 months. This 5 month time frame of being off
bromocriptine is similar to her ﬁrst presentation at about 5months
during her pregnancy. Her prolactin level was again elevated. This
was discussedwith her endocrinologist and the bromocriptinewas
reinitiated. The breast changes resolved 1 week after the patient
restarted the bromocriptine.
3. Discussion
Idiopathic granulomatous mastitis (IGM) is a disease with no
known cause and is diagnosed after othermore common etiologies
of breastmass have been ruled out (i.e., malignancy, infectionmost
notably tuberculosis). There is no consensus on the recommended
treatment.
Coccidioides immitis is an environmental dimorphic fungus
endemic to the desert regions. Erythema nodosum is a common
ﬁnding, and is associatedwith amore indolent course [10,11]. Coc-
cidioides infection is rare in pregnancy, even in endemic areas.
Wack, et al. reported 10 cases among 47,120 pregnancies in Tucson,
Arizona [12]. In pregnancy, Coccidiodomycosis is most often diag-
nosed via serologic testing of the maternal serum. As with other
infections, IGM antibodies are initially positive (in about 75% of
CASE REPORT – OPEN ACCESS
10 M.E. Bouton et al. / International Journal of Surgery Case Reports 10 (2015) 8–11
peoplewith primary infection) and later IgG titers becomepositive.
IgG antibodies usually disappear in several months if the infection
resolves [13].
The current patient had a known prolactinoma, however,
treatment with bromocriptine was stopped by necessity during
pregnancy. The course of IGM in this patient appears to correlate
with treatment of her prolactinoma. The patient initially demon-
strated signiﬁcant clinical improvement of the mass coinciding
with stopping the antifungal medication and then complete res-
olution after treatment with bromocriptine for her prolactinoma
was reinstituted after delivery. In addition, the early signs of the
second episode recently seen at 33 months after resolution of the
initial episode occurred after being off bromocriptine again for 5
months. This time frame of 5 months was similar to the time that
had elapsed prior to her intial episode as she presented at 25weeks
during her pregnancy. During her visit, the patient stated that she
felt this second presentation was similar to how her initial episode
started. Her prolactin level had been documented to be elevated for
at least 5 months.
Although IGM has no known cause, hormones likely play a sig-
niﬁcant role in the etiology as it is almost exclusively seen in young,
fertile, andparouswomen. It also commonly occurs in pregnancyor
during lactation. Review of the literature further demonstrates an
unusually high incidence of hyperprolactinemia in these patients
[3]. In addition, reports exist of patients with IGM who have pro-
lactinoma [3]. It is possible that at least in some, IGM is caused or
exacerbated by prolactin levels, and future inquiry is warranted.
The fact that the onset and resolution of this patient’s IGM coin-
cidedwith stopping and restarting bromocriptine on two occasions
further supports this possibility.
Treatment recommendations for IGM vary widely but antibi-
otics and antifungalmedications are not recommended. In the past,
surgical recommendations have extend from simple excision up
to and including mastectomy. Although simple excision of IGM
masses was the most frequently reported surgical treatment this
may not add assurance for cure as recurrences have been reported
to be as high as 21% [14]. There are many reports of mastectomy
to treat IGM. Recurrence or residual disease, however, may still
occur after mastectomy [15,16]. Most have moved away from sur-
gical management of IGM. Non-surgical recommendations include
pharmacologic (i.e., steroids, methotrexate, azathioprine, tubercu-
losis medications) or close observation [1,3,6,17]. A recent case
report in a patient with systemic lupus erythematosus (SLE) and
prolactinoma found that treatment of both conditions (immuno-
suppressive therapy for SLE and bromocriptine for prolactinoma)
were necessary to maintain remission of IGM [18]. In the largest
series to date, Pandey, et al. reported that 23% of 49 IGM patients
had recurrenceafter corticosteroid treatment [1]. Closeobservation
with reassurance and patient education about the natural history
of the process has also been used with similar results [3].
4. Conclusion
IGM is a previously rare clinical entity that is becoming more
commonly recognized. Management with observation is a reason-
able option and can help avoid unnecessary testing and treatment.
Prolactin is one of the hormones which may play a role in the
pathophysiology of the disease process.
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